SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-123106"
 

Search: id:"swepub:oai:DiVA.org:uu-123106" > Potential utility o...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes

Mokhtari, Dariush (author)
Uppsala universitet,Institutionen för medicinsk cellbiologi
Welsh, Nils (author)
Uppsala universitet,Institutionen för medicinsk cellbiologi
 (creator_code:org_t)
2010
2010
English.
In: Clinical Science. - 0143-5221 .- 1470-8736. ; 118:3-4, s. 241-247
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Altered tyrosine kinase signalling has been implicated in several diseases, paving the way for the development of small-molecule TKIs (tyrosine kinase inhibitors). TKIs such as imatinib, sunitinib and dasatinib are clinically used for treating chronic myeloid leukaemia, gastrointestinal stromal tumours and other malignancies. In addition to their use as anti-cancer agents, increasing evidence points towards an anti-diabetic effect of these TKIs. Imatinib and other TKIs counteract diabetes not only in non-obese diabetic mice, but also in streptozotocin diabetic mice, db/db mice, high-fat-treated rats and humans with T2D (Type 2 diabetes). Although the mechanisms of protection need to be investigated further, the effects of imatinib and other TKIs in human T2D and the rapidly growing findings from animal models of T1D (Type 1 diabetes) and T2D are encouraging and give hope to improved treatment of human diabetes. In the present article, we review the anti-diabetic effects of TKIs which appear to involve both protection against beta-cell death and improved insulin sensitivity. Considering the relatively mild side effects of TKIs, we hypothesize that TKIs could be used to treat new-onset T1D, prevent T1D in individuals at high risk of developing the disease, treat the late stages of T2D and improve the outcome of islet transplantation.

Keyword

β-cell
diabetes
imatinib
c-Abl
platelet-derived growth factor receptor (PDGFR)
tyrosine kinase inhibitor
MEDICINE
MEDICIN

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Find more in SwePub

By the author/editor
Mokhtari, Darius ...
Welsh, Nils
Articles in the publication
Clinical Science
By the university
Uppsala University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view